Clinical Trial Update: Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating high-dose melphalan with autologous stem cell transplantation in patients with light chain amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light Chain Amyloidosis

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: Herbert Irving Comprehensive Cancer Center | Conditions: Amyloidosis | Phase 2 | Status: COMPLETED